Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Executive Summary
Professional education efforts will be the centerpiece of Bristol-Myers Squibb's late-February launch of the rheumatoid arthritis treatment Orencia (abatacept) under the company's voluntary direct-to-consumer advertising moratorium for new products
You may also be interested in...
Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said
Orencia Outperforming Rituxan In RA, Bristol Says; Branded DTC To Start Soon
Physicians more frequently prescribe Bristol-Myers Squibb's Orencia than Genentech/Biogen Idec's Rituxan for rheumatoid arthritis, Bristol Worldwide Pharmaceuticals President Lamberto Andreotti said
Rituxan RA Approval Raises The Stakes, But With A Lower Price
Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)